New Blood Test Detects Alzheimer's Years Earlier

A novel blood test has emerged that analyzes the structural folding of amino acids, offering a new method for detecting the earliest biological indicators of Alzheimer's disease. Published in Nature Aging, the study involved analyzing blood plasma from over 500 individuals.

The findings reveal that structural variations in three specific proteins are strongly associated with an individual's Alzheimer's status. These proteins are involved in immune signaling, protein folding regulation, and fat transport within the bloodstream.

This technique accurately differentiated between individuals who were cognitively normal, those with mild cognitive impairment, and patients diagnosed with Alzheimer's. Machine learning was employed to identify patterns linked to disease progression, focusing on how exposed or buried specific areas of amino acid chains were.

Currently, Alzheimer's diagnosis relies on detecting amyloid plaques and tau tangles. However, this new method aligns with the growing understanding that Alzheimer's involves a broader failure of proteostasis, the system responsible for maintaining correct protein folding. The researchers suggest that disruptions in the brain's proteostasis may manifest as similar structural changes in circulating blood proteins.

This multi-marker panel, based on plasma protein structural alterations, is considered a promising diagnostic advancement. It could significantly enhance early detection of Alzheimer's disease and provide valuable insights for clinical trials, potentially leading to improved therapeutic outcomes.